2024
High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine
Ottesen T, Wickersham J, Lawrence J, Antoniak S, Zezuilin O, Polonsky M, Antonyak S, Rozanova J, Dvoriak S, Pykalo I, Filippovych M, Altice F. High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine. PLOS ONE 2024, 19: e0305086. PMID: 39028735, PMCID: PMC11259278, DOI: 10.1371/journal.pone.0305086.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy prescriptionAntiretroviral therapyCD4 countSubstance use disordersIncreased levels of stigmaNational sampleLevel of stigmaIndependent of risk groupSuboptimal antiretroviral therapyInitiate antiretroviral therapyPopulation of peopleHIV expertsHIV incidenceHIV physiciansHIV treatmentKey populationsTransgender womenAntiretroviral treatmentFeeling thermometerDrinking alcoholSex workersPhysiciansSex partnersPWHRisk groupsHIV Activist Identity, Commitment, and Orientation Scale (HAICOS): Psychometric Evaluation to Assess Clinician’s Propensity Towards HIV Activism in Malaysia
Chong N, Azwa I, Hassan A, Mousavi M, Wong P, Ng R, Saifi R, Basri S, Omar S, Walters S, Collier Z, Haddad M, Altice F, Kamarulzaman A, Earnshaw V. HIV Activist Identity, Commitment, and Orientation Scale (HAICOS): Psychometric Evaluation to Assess Clinician’s Propensity Towards HIV Activism in Malaysia. AIDS And Behavior 2024, 28: 2780-2792. PMID: 38806844, DOI: 10.1007/s10461-024-04381-4.Peer-Reviewed Original ResearchConceptsExploratory factor analysisHIV-related stigmaIntra-class correlation coefficientPrimary care physiciansTest-retest reliabilityCronbach's alpha valuesOrientation ScaleCare physiciansStigma-relatedPsychometric evaluationHIV treatmentHIV activityAlpha valuesPsychometric qualitiesActivist identitiesHIVClinical practiceFactor analysisCliniciansCorrelation coefficientDay-to-dayStructured activitiesCronbachStigmaPhysicians
2022
Advancing data to care strategies for persons with HIV using an innovative reconciliation process
Villanueva M, Miceli J, Speers S, Nichols L, Carroll C, Jenkins H, Altice F. Advancing data to care strategies for persons with HIV using an innovative reconciliation process. PLOS ONE 2022, 17: e0267903. PMID: 35511958, PMCID: PMC9071117, DOI: 10.1371/journal.pone.0267903.Peer-Reviewed Original ResearchConceptsDisease intervention specialistsHIV care continuumCare continuumNon-randomized patientsPublic health surveillance dataOngoing HIV transmissionClinic visit dataHealth surveillance dataPublic health surveillanceHIV clinicHIV eliminationViral loadHIV transmissionCare engagementCopies/Clinic staffClinic dataYale University SchoolVisit dataHealth surveillancePWHSurveillance dataPatientsCells/Intervention specialists
2021
An expanding HIV epidemic among older adults in Ukraine: Implications for patient-centered care
Rozanova J, Zeziulin O, Rich KM, Altice FL, Kiriazova T, Zaviryukha I, Sosidko T, Gulati K, Carroll C, Shenoi SV. An expanding HIV epidemic among older adults in Ukraine: Implications for patient-centered care. PLOS ONE 2021, 16: e0256627. PMID: 34591848, PMCID: PMC8483339, DOI: 10.1371/journal.pone.0256627.Peer-Reviewed Original ResearchConceptsStandardized mortality ratioMortality rateCause standardized mortality ratioTime of diagnosisGeneral population ratesLate-stage HIVAge-matched groupHigh mortality ratePatient-centered careIncident HIVHIV diagnosisHIV testingHIV incidenceHIV treatmentHIV epidemicMortality ratioTreatment strategiesGeneral populationHIVMortality trendsAge groupsEECA countriesTreatment programSame calendar yearOlder peopleAssociation Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Domingo P, Mur I, Mateo G, Gutierrez M, Pomar V, de Benito N, Corbacho N, Herrera S, Millan L, Muñoz J, Malouf J, Molas M, Asensi V, Horcajada J, Estrada V, Gutierrez F, Torres F, Perez-Molina J, Fortun J, Villar L, Hohenthal U, Marttila H, Vuorinen T, Nordberg M, Valtonen M, Frigault M, Mansour M, Patel N, Fernandes A, Harvey L, Foulkes A, Healy B, Shah R, Bensaci A, Woolley A, Nikiforow S, Lin N, Sagar M, Shrager H, Huckins D, Axelrod M, Pincus M, Fleisher J, Lampa J, Nowak P, Vesterbacka J, Rasmuson J, Skorup P, Janols H, Niward K, Chatzidionysiou K, Asgeirsson H, Parke Å, Blennow O, Svensson A, Aleman S, Sönnerborg A, Henter J, Horne A, Al-Beidh F, Angus D, Annane D, Arabi Y, Beane A, Berry S, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, Cove M, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Ichihara N, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgommery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Reyes F, Rowan K, Saito H, Santos M, Seymour C, Shankar-Hari M, Turgeon A, Turner A, van Bentum-Puijk W, van de Veerdonk F, Webb S, Zarychanski R, Baillie J, Beasley R, Cooper N, Fowler R, Galea J, Hills T, King A, Morpeth S, Netea M, Ogungbenro K, Pettila V, Tong S, Uyeki T, Youngstein T, Higgins A, Lorenzi E, Berry L, Salama C, Rosas I, Ruiz-Antorán B, Muñez Rubio E, Ramos Martínez A, Campos Esteban J, Avendaño Solá C, Pizov R, Sanz Sanz J, Abad-Santos F, Bautista-Hernández A, García-Fraile L, Barrios A, Gutiérrez Liarte Á, Alonso Pérez T, Rodríguez-García S, Mejía-Abril G, Prieto J, Leon R, VEIGA V, SCHEINBERG P, FARIAS D, PRATS J, CAVALCANTI A, MACHADO F, ROSA R, BERWANGER O, AZEVEDO L, LOPES R, DOURADO L, CASTRO C, ZAMPIERI F, AVEZUM A, LISBOA T, ROJAS S, COELHO J, LEITE R, CARVALHO J, ANDRADE L, SANDES A, PINTÃO M, SANTOS S, ALMEIDA T, COSTA A, GEBARA O, FREITAS F, PACHECO E, MACHADO D, MARTIN J, CONCEIÇÃO F, SIQUEIRA S, DAMIANI L, ISHIHARA L, SCHNEIDER D, DE SOUZA D, Hermine O, Mariette X, Tharaux P, Resche Rigon M, Porcher R, Ravaud P, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Tibi A, Yazdanpanah Y, Dougados M, Bureau S, Horby P, Landray M, Baillie K, Buch M, Chappell L, Day J, Faust S, Haynes R, Jaki T, Jeffery K, Juszczak E, Lim W, Mafham M, Montgomery A, Mumford A, Thwaites G, Kamarulzaman A, Syed Omar S, Ponnampalavanar S, Raja Azwa R, Wong P, Kukreja A, Ong H, Sulaiman H, Basri S, Ng R, Megat Johari B, Rajasuriar R, Chong M, Neelamegam M, Syed Mansor S, Zulhaimi N, Lee C, Altice F, Price C, Malinis M, Hasan M, Wong C, Chidambaram S, Misnan N, Mohd Thabit A, Sim B, Bidin F, Mohd Abd Rahim M, Saravanamuttu S, Tuang W, Mohamed Gani Y, Thangavelu S, Tay K, Ibrahim N, Halid L, Tan K, Mukri M, Arip M, Koh H, Syed Badaruddin S, Raja Sureja L, Chun G, TORRE-CISNEROS J, MERCHANTE N, LEON R, CARCEL S, GARRIDO J, Galun E, Soriano A, Martínez J, Castán C, Paredes R, Dalmau D, Carbonell C, Espinosa G, Castro P, Muñóz J, Almuedo A, Prieto S, Pacheco I, Ratain M, Pisano J, Strek M, Adegunsoye A, Karrison T, Jozefien D, Karel F.A. V, Elisabeth D, Cedric B, Bastiaan M, Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty J, Berry L, Broman N, Cavalcanti A, Colman R, De Buyser S, Derde L, Domingo P, Omar S, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon A, Haynes R, Hermine O, Horby P, Horick N, Kumar K, Lambrecht B, Landray M, Leal L, Lederer D, Lorenzi E, Mariette X, Merchante N, Misnan N, Mohan S, Nivens M, Oksi J, Perez-Molina J, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan A, Ravaud P, Reid P, Rutgers A, Sancho-Lopez A, Seto T, Sivapalasingam S, Soin A, Staplin N, Stone J, Strohbehn G, Sunden-Cullberg J, Torre-Cisneros J, Tsai L, van Hoogstraten H, van Meerten T, Veiga V, Westerweel P, Murthy S, Diaz J, Marshall J, Sterne J. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA 2021, 326: 499-518. PMID: 34228774, PMCID: PMC8261689, DOI: 10.1001/jama.2021.11330.Peer-Reviewed Original ResearchConceptsIL-6 antagonistsUsual careCause mortalitySummary odds ratiosOdds ratioEligible trialsMechanical ventilationClinical trialsMortality riskSecondary infectionCOVID-19Primary outcome measureAbsolute mortality riskBias assessment toolRisk of biasStudy selection criteriaCochrane riskSecondary outcomesI2 statisticPlaceboOutcome measuresMAIN OUTCOMEPatientsAdditional trialsPrimary analysisAcceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study
Shelby T, Zhou X, Barber D, Altice F. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study. Journal Of Medical Internet Research 2021, 23: e25428. PMID: 34259640, PMCID: PMC8319773, DOI: 10.2196/25428.Peer-Reviewed Original ResearchConceptsSyringe services programHarm reduction servicesReduction servicesSecondary outcomesMHealth appsParticipant characteristicsHarm reduction needsHome deliveryMost participantsRespondent-driven samplingPrimary outcomeSuboptimal accessIndependent correlatesMedical recordsDrug injectionMobile health appsPWIDSummary scoresMedication remindersSSP usePoisson regressionUnstable housingVulnerable populationsSyringe deliveryHealth appsModelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, Rahimi-Movaghar A, Alavi M, Young AM, Havens JR, Miller WC, Hickman M, Vickerman P. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. The Lancet Psychiatry 2021, 8: 301-309. PMID: 33640039, PMCID: PMC8255389, DOI: 10.1016/s2215-0366(20)30538-1.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentDrug-related deathsOAT coverageDrug-related harmAgonist treatmentHepatitis C virus transmissionC virus transmissionOverall health benefitsUK National InstituteNational InstituteHIV 0OAT retentionHIV mortalityInjury 3Opioid dependenceMortality outcomesUS National InstitutesHCV-2Overdose deathsSignificant additional effectIntervention effectsDrug abuseHealth benefitsMortalityDeath
2020
Response to the COVID-19 Outbreak in Urban Settings in China
Ni Z, Lebowitz ER, Zou Z, Wang H, Liu H, Shrestha R, Zhang Q, Hu J, Yang S, Xu L, Wu J, Altice FL. Response to the COVID-19 Outbreak in Urban Settings in China. Journal Of Urban Health 2020, 98: 41-52. PMID: 33258088, PMCID: PMC7703725, DOI: 10.1007/s11524-020-00498-8.Peer-Reviewed Original ResearchHazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIVThe real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatmentTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesSafety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy
Gonzales P, Grieco A, White E, Ding R, Ignacio RB, Pinto-Santini D, Lama JR, Altice FL, Duerr A. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLOS ONE 2020, 15: e0228433. PMID: 32134956, PMCID: PMC7058313, DOI: 10.1371/journal.pone.0228433.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAntiretroviral therapyClinical adverse eventsAdverse eventsTransgender womenUse disordersDouble-blind randomized placebo-controlled trialMSM/transgender womenRandomized placebo-controlled trialART-naïve participantsPossibility of hepatotoxicityPlacebo-controlled trialSerious adverse eventsHIV-positive menMedication-assisted therapyProportion of subjectsAdverse event dataMultiple new medicationsOral naltrexoneStudy medicationTransaminase elevationPlacebo armNTX treatmentTreatment armsNew medications
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART dosesTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testingEstimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States
Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, Altice FL. Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. International Journal Of Environmental Research And Public Health 2019, 16: 1592. PMID: 31067679, PMCID: PMC6539923, DOI: 10.3390/ijerph16091592.Peer-Reviewed Original ResearchConceptsYoung Latino MSMYoung Black MSMPre-exposure prophylaxisBlack MSMLatino MSMPrEP useHIV Incidence Risk IndexHuman immunodeficiency virus (HIV) transmissionUse of PrEPNon-PrEP usersLowest NNTHIV infectionNNT valuesHIV prevalenceHIV epidemicHIV preventionMSM populationSubsequent infectionInfection reductionMSMPrevalenceIncidenceVirus transmissionPrEPProphylaxisHIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients
Shrestha R, Altice FL, Copenhaver MM. HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 166-173. PMID: 30383588, PMCID: PMC6331231, DOI: 10.1097/qai.0000000000001891.Peer-Reviewed Original ResearchConceptsOptimal ART adherenceAntiretroviral therapyMethadone-maintained patientsMethadone maintenance treatmentART adherenceMaintenance treatmentHIV treatment outcomesHIV-positive patientsOpioid agonist therapyMultivariable logistic regressionHIV risk behaviorsExplanatory pathwaysAgonist therapySuboptimal adherenceMedication adherenceHIV treatmentTreatment outcomesHIV stigmaPatientsLogistic regressionHIVPrevention initiativesTherapyAdherenceSignificant correlatesEvaluation of HIV risk and outcomes in a nationally representative sample of incarcerated women in Azerbaijan, Kyrgyzstan, and Ukraine
Ranjit YS, Azbel L, Krishnan A, Altice FL, Meyer JP. Evaluation of HIV risk and outcomes in a nationally representative sample of incarcerated women in Azerbaijan, Kyrgyzstan, and Ukraine. AIDS Care 2019, 31: 793-797. PMID: 30701981, PMCID: PMC6510603, DOI: 10.1080/09540121.2019.1573969.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveAzerbaijanCommunicable DiseasesComorbidityContinuity of Patient CareFemaleHealth Services AccessibilityHepatitis CHIV InfectionsHumansKyrgyzstanMaleMental DisordersMiddle AgedPrevalencePrisonersPrisonsSubstance-Related DisordersSurveys and QuestionnairesSyphilisUkraineConceptsAlcohol use disorderAntiretroviral therapyHIV preventionHIV riskHIV care continuumCells/μLHigh-risk groupComorbid substance useEffective HIV preventionGlobal HIV preventionHigh rateHepatitis CIncarcerated womenHIV testingHIV incidenceHIV prevalencePsychiatric comorbidityDrug injectionRepresentative sampleCare continuumRisk groupsPsychiatric disordersMost womenUse disordersTreatment interventionsUsing nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support
Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal Of Substance Use And Addiction Treatment 2019, 100: 18-28. PMID: 30898324, PMCID: PMC6432946, DOI: 10.1016/j.jsat.2019.01.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderNominal group techniquePharmacologic therapyUse disordersSyringe exchange programsIndividual-level barriersEvidence-based interventionsAddiction treatment centersEvidence-based strategiesOUD treatmentPharmacologic treatmentSpecific medicationsTreatment optionsPharmacologic propertiesMedicationsDecision aidPatient considerationsSide effectsTreatment centersOpioid crisisSpecific knowledge gapsGroup techniqueDecision aid developmentTreatmentTherapyRetention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia
Chandra DK, Bazazi AR, Solim M, Kamarulzaman A, Altice FL, Culbert GJ. Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia. HIV Research & Clinical Practice 2019, 20: 12-23. PMID: 31303149, PMCID: PMC6698147, DOI: 10.1080/15284336.2019.1603433.Peer-Reviewed Original ResearchConceptsClinical trialsStudy visitHIV clinical trialsOpioid dependenceMethadone initiationStudy retentionHolistic Health Recovery ProgramPrison releaseHIV risk reduction interventionsRisk reduction interventionsIncarcerated menStandard careMethadone treatmentReduction interventionsStudy participantsFactorial trialHIVBehavioral interventionsTrialsVisitsMost participantsInterventionMenCommunity reentryRecovery program
2018
Evaluating Physicians’ Intention to Discriminate Against Patients Living with HIV in Malaysia
Tee YC, Earnshaw VA, Altice FL, Jin H, Kamarulzaman A, Wickersham JA. Evaluating Physicians’ Intention to Discriminate Against Patients Living with HIV in Malaysia. AIDS And Behavior 2018, 23: 1039-1047. PMID: 30560483, PMCID: PMC6459712, DOI: 10.1007/s10461-018-2362-4.Peer-Reviewed Original ResearchConceptsStigma-related constructsMajor university hospitalClasses of patientsCross-sectional online surveyNon-surgical specialtiesMore HIVSocio-demographic characteristicsUniversity HospitalHIV preventionTreatment strategiesPWHClinical experienceHIVBetter carePhysiciansMultivariate linear regressionMedical settingsInternational HIV preventionMost participantsLinear regressionPatientsCarePresent studyParticipantsStigma